ES2194536T3 - Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos. - Google Patents

Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos.

Info

Publication number
ES2194536T3
ES2194536T3 ES99960277T ES99960277T ES2194536T3 ES 2194536 T3 ES2194536 T3 ES 2194536T3 ES 99960277 T ES99960277 T ES 99960277T ES 99960277 T ES99960277 T ES 99960277T ES 2194536 T3 ES2194536 T3 ES 2194536T3
Authority
ES
Spain
Prior art keywords
duloxetine
combination
inflammatory drugs
steroid anti
steroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99960277T
Other languages
English (en)
Inventor
Smriti Iyengar
Carrie Kimberly Jones
Harlan Edgar Shannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2194536T3 publication Critical patent/ES2194536T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Processing Of Meat And Fish (AREA)

Abstract

El uso de duloxetina o una sal o solvato de la misma farmacéuticamente aceptable en combinación con uno o más NSAID para la fabricación de un medicamento para tratar el dolor.
ES99960277T 1998-11-13 1999-11-10 Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos. Expired - Lifetime ES2194536T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10837098P 1998-11-13 1998-11-13

Publications (1)

Publication Number Publication Date
ES2194536T3 true ES2194536T3 (es) 2003-11-16

Family

ID=22321828

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99960277T Expired - Lifetime ES2194536T3 (es) 1998-11-13 1999-11-10 Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos.

Country Status (9)

Country Link
US (1) US6245802B1 (es)
EP (1) EP1135121B1 (es)
JP (1) JP2002529499A (es)
AT (1) ATE234090T1 (es)
AU (1) AU1718400A (es)
CA (1) CA2350531A1 (es)
DE (1) DE69905938T2 (es)
ES (1) ES2194536T3 (es)
WO (1) WO2000028980A2 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6586458B1 (en) * 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
DE60115465T2 (de) * 2000-08-29 2006-08-03 Nobex Corp. Immunoregulierende verbindungen, deren derivate und ihre verwendung
US8680081B2 (en) * 2000-08-29 2014-03-25 Peter Van Patten Prophylactic treatment of migraine
US6528076B2 (en) 2001-07-06 2003-03-04 Magic Herb Corp. Topical compositions and methods for treating pain
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
ES2399880T3 (es) * 2002-03-15 2013-04-04 Cypress Bioscience, Inc. Milnaciprán para el tratamiento del síndrome del intestino irritable
US20030232805A1 (en) * 2002-04-24 2003-12-18 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
AU2003229408A1 (en) 2002-06-10 2003-12-22 Philippe Kriwin Oral antidepressant formulation comprising a selective serotonin_reuptake inhibitor
US20100189797A1 (en) * 2002-06-10 2010-07-29 Julien Mendlewicz Oral antidepressant formulation
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
GB0229583D0 (en) * 2002-12-19 2003-01-22 Cipla Ltd A process for preparing duloxetine and intermediates for use therein
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US7332183B2 (en) * 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
AU2004247076A1 (en) * 2003-06-06 2004-12-23 Glaxo Group Limited Composition comprising triptans and NSAIDs
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
CA2543640C (en) * 2003-10-29 2010-06-01 Philippe Kriwin Oral antidepressant formulation comprising acetylsalicylic acid to accelerate onset of action
WO2005051378A1 (en) * 2003-11-21 2005-06-09 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
WO2005108683A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
EP4047096A1 (en) 2004-06-28 2022-08-24 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US8093408B2 (en) * 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US8153824B2 (en) * 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
WO2007005644A2 (en) * 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
BRPI0613611A2 (pt) * 2005-07-22 2011-01-18 Myriad Genetics Inc formulações de alta concentração de fármaco e formas de dosagens
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
WO2007062119A1 (en) * 2005-11-23 2007-05-31 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
WO2007134168A2 (en) * 2006-05-10 2007-11-22 Dr. Reddy's Laboratories Ltd. Process for preparing duloxetine
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
WO2008009665A1 (en) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Treatment of pain
US20090162421A1 (en) * 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
MX2010006608A (es) * 2007-12-21 2010-10-05 Paz Arzneimittelentwicklung Composiciones farmaceuticas y produccion y uso de las mismas en el tratamiento de neuropatias asociadas con el dolor.
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
EP3428278A1 (en) 2008-10-24 2019-01-16 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for dmd
CN103003430A (zh) 2009-11-12 2013-03-27 西澳大利亚大学 反义分子和治疗疾病的方法
EP2332930A1 (en) * 2009-11-23 2011-06-15 Laboratorios Del. Dr. Esteve, S.A. Salts of duloxetine and NSAIDs for the treatment of pain
CA2814763C (en) 2011-01-11 2019-05-28 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
JP6148182B2 (ja) 2011-03-09 2017-06-14 シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. 複素環式リンカーを有する活性薬剤プロドラッグ
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
RU2506077C1 (ru) * 2013-01-25 2014-02-10 Общество С Ограниченной Ответственностью "Валента-Интеллект" Комбинация для профилактики, коррекции и терапии боли, связанной с нейродегенерацией или ассоциированной с соматоформными расстройствами
EA202090946A3 (ru) 2013-03-14 2021-07-30 Сарепта Терапьютикс, Инк. Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
NZ631289A (en) 2013-03-15 2017-08-25 Sarepta Therapeutics Inc Improved compositions for treating muscular dystrophy
US10272097B2 (en) 2013-12-24 2019-04-30 Virginia Commonwealth University Uses of oxygenated cholesterol sulfates (OCS)
CN114404409A (zh) * 2022-02-23 2022-04-29 江苏海洋大学 一种可治疗疼痛的药物组合及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035584A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
JP2002503224A (ja) * 1997-04-11 2002-01-29 エリ リリー アンド カンパニー 疼痛を処置するための組成物
WO1998046601A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Composition for treating pain
US5942530A (en) * 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain

Also Published As

Publication number Publication date
WO2000028980A3 (en) 2000-07-27
US6245802B1 (en) 2001-06-12
DE69905938D1 (de) 2003-04-17
EP1135121A2 (en) 2001-09-26
CA2350531A1 (en) 2000-05-25
DE69905938T2 (de) 2003-11-13
AU1718400A (en) 2000-06-05
ATE234090T1 (de) 2003-03-15
WO2000028980A2 (en) 2000-05-25
EP1135121B1 (en) 2003-03-12
JP2002529499A (ja) 2002-09-10

Similar Documents

Publication Publication Date Title
ES2194536T3 (es) Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos.
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
HUP0004532A2 (en) Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
ATE425253T1 (de) Tribonektine
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
PT1193270E (pt) Pirrolobenzodiazepinas
NO20006630L (no) Farmasöytisk sammensetning for behandlingen av diabetes
DK1032376T3 (da) Anvendelse af benzhydrylsulfinylderivater til behandling af søvnighed af medicinal oprindelse
NO970067L (no) Nytt farmasöytisk preparat for smertebehandling
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
BR9814040A (pt) Agudo no pulmão com fibrose com antagonistas de avb6
LV12624B (lv) Tienilazolilalkosietanamini to iegusanas panemiens un pielietojums medikamentu legusana
DE69935720D1 (de) Diamino-propanol-verbindungen zur behandlung von ischaemien
ITMI981774A0 (it) Composizioni farmaceutiche ad attivita&#39; analgesica
BR9707247A (pt) Diidrobenzofurano e compostos relacionados úteis como agentes antiinflamatórios
ES2194003T3 (es) Huperzina a racemica.
DK0946157T3 (da) Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte
HUP0000137A2 (hu) Szabályozott hatóanyag-felszabadulású analgetikumot tartalmazó gyógyszerkészítmény
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
EE200100281A (et) Analgeetiline ravimkoostis
ATE344664T1 (de) Verbesserte methode zur eradikation von helicobacter pylori
ATE270551T1 (de) Kombinationspräparat aus 2-methylthiazolidin-2,4- dicarbonsäure und paracetamol
NO20005548L (no) Mykobakterieinhibitorer
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
TR199801798T2 (xx) Otizm tedavisi.